A Phase 3 interventional study of Furoscix Infusor in Heart Failure, sponsored by scPharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-24.
Sponsored by scPharmaceuticals, Inc. (part of Mannkind Corporation) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.
Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,130th largest by enrollment of the 1,601 interventional ones that give a count, is one of 98 that started in 2020, is one of 147 in phase 3, and was the 1,246th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80
AnaCardio AB · Sites in United States, Bulgaria, Canada and 5 more countries
Ages 18–85
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18–80 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,157 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 174 · Phase 2 313 · Phase 3 177 · Phase 4 139
First in 1983; this study’s year is marked. 98 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 65 across the 1,601 interventional studies, 150 across the 551 observational. Of the 1,510 that completed or were terminated, 629 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
746 of 2,157 have an industry lead sponsor. The 10 most frequent:
This study is registered under scPharmaceuticals, Inc., one of the names counted as Mannkind Corporation. Under that name alone:
scPharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Mannkind Corporation has 7 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
136 of the studies in Heart Failure with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02901184Phase 3Uppsala UniversitySpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction | 2026-12 |
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06008197Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | 2027-11 |
Add all 136 to your calendar (.ics) → With an account.
Among the 2,157 studies in Heart Failure with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in patients initially presenting to the emergency department.
The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor.
The study objectives are:
This adaptive clinical trial will include a prospective treatment arm (i.e., Furoscix administered via the Furoscix Infusor) administered outside the hospital that will be compared to a propensity-matched historical control arm of patients admitted to the hospital for ≤ 72 hours (i.e., Treatment As Usual (TAU)) that will be derived from administrative claims data. Eligible patients for the Furoscix arm will be patients with HF and fluid overload who initially present to the emergency department (ED) and who are expected to require parenteral diuresis.
If it is determined by the investigator that the patient requires parenteral diuresis or continued diuresis outside of the ED care setting and meets all study eligibility criteria, he/she may be consented and enrolled into the study.
The treatment comprises a preprogrammed bi-phasic 5-hour drug administration. Subjects will be instructed on the use of the Furoscix Infusor by the investigator and/or study staff in accordance with the instructions for use. The initial dose of the study product may be administered in the ED or at home. Additional doses will be provided to the subject for self-administration or administration by a caregiver in the home setting as directed by the investigator or study staff. The total duration in days and total number of doses of the initial therapy will be determined by the investigator based on an estimated volume of diuresis desired to transition patient back to their oral diuretic maintenance therapy. Subjects will receive scheduled at-home telephone calls from a HF nurse on Days 1 and 7 and one call between Days 14-21. Planned in-clinic visits will be conducted between Day 2-4 and then Day 30. Unscheduled at-home telephone calls by a HF nurse and unscheduled in-clinic visits may be performed if felt clinically indicated by the study team or the clinical provider.
The study period will be up to 30 days after enrollment. All outcomes will be assessed up to 30 days after the initial discharge from the emergency department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signs of extracellular volume expansion, defined as one or more of the following:
After initial emergency department evaluation and treatment (i.e., at the time of the care transition decision*), candidates for parenteral diuresis outside of the hospital, defined as all the following:
Exclusion Criteria:
Estimated \< 30 mL per minute by Cockcroft-Gault equation
CrCl (mL/min) = {(140 - age) x Lean Body Weight (kg)/Serum Creatinine (mg/dL) x 72} (x 0.85 if female)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
Combination Product: Furoscix Infusor
The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Healthcare Utilization Costs
The difference in the overall and heart failure related healthcare costs between subjects treated with the Furoscix Infusor through 30 days post discharge from the emergency department compared to matched controls treated in the hospital for ≤ 72 hours through 30 days post discharge.
Time frame: Day 0 - Day 30
Heart-Failure Related Hospital Admissions
The HF-related admissions for the Furoscix patients compared to Control patients.
Time frame: Day 0 - Day 30
All-Cause Hospital Admissions
The differences in the percentage of subjects with an all-cause hospitalization in the Furoscix group and all-cause 30-day rehospitalization in the Control group in the 30 day follow-up period
Time frame: Day 0 - Day 30
Heart-Failure Related Emergency Department Visits
The differences in the percentage of patients with HF-related emergency department visits in the Furoscix group and in the Control group in the 30 day follow-up period
Time frame: Day 0 - Day 30
Heart-Failure Related Clinic Visits
The differences in the percentage of patients with HF-related clinic visits in the Furoscix group and in the Control group in the 30 day follow-up period
Time frame: Day 0 - Day 30
KCCQ-12 Scores
The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures a patient's self-reported overall health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL). The KCCQ-12 overall summary score is the sum of responses from all 12 items ranging from 0 to 100 with higher scores to indicate better health status.
Time frame: 30 Days
Mean Change in NT-proBNP and BNP
Change in NT-proBNP and BNP change from baseline during the study period is summarized for the Furoscix group
Time frame: Day 0 - Day 30
Comfort of Wear Questionnaire
The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
Time frame: Day 0 - Day 2-4 study visit
Comfort of Wear Questionnaire: Interference With Activities Daily Living
The Furoscix group was administered a Comfort of Wear Questionnaire on Day 2-4. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
Time frame: Day 0 - Day 2-4 study visit
Comfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction
The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
Time frame: Day 0 - Day 2-4 study visit
| Milestone | Furoscix Infusor Prospective Treatment |
|---|---|
| Started | 25 |
| Completed | 24 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
The difference in the overall and heart failure related healthcare costs between subjects treated with the Furoscix Infusor through 30 days post discharge from the emergency department compared to matched controls treated in the hospital for ≤ 72 hours through 30 days post discharge.
| US Dollars | Furoscix Infusor Prospective Treatment |
|---|---|
| HF-related healthcare costs | 2920.30 ± 7073.20 |
| Overall healthcare costs | 7512.30 ± 11,905.50 |
The HF-related admissions for the Furoscix patients compared to Control patients.
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| Heart-Failure Related Hospital Admissions | 1 |
The differences in the percentage of subjects with an all-cause hospitalization in the Furoscix group and all-cause 30-day rehospitalization in the Control group in the 30 day follow-up period
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| All-Cause Hospital Admissions | 6 |
The differences in the percentage of patients with HF-related emergency department visits in the Furoscix group and in the Control group in the 30 day follow-up period
| Participants | Furoscix Infusor Prospective Treatment | Matched Historical Control |
|---|---|---|
| Heart-Failure Related Emergency Department Visits | 1 | 4 |
The differences in the percentage of patients with HF-related clinic visits in the Furoscix group and in the Control group in the 30 day follow-up period
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| Heart-Failure Related Clinic Visits | 24 |
The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures a patient's self-reported overall health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL). The KCCQ-12 overall summary score is the sum of responses from all 12 items ranging from 0 to 100 with higher scores to indicate better health status.
| score on a scale | Furoscix Infusor Prospective Treatment - Baseline | Furoscix Infusor Prospective Treatment - Day 30 |
|---|---|---|
| Summary Score | 29.9 ± 22.8 | 42.8 ± 28.4 |
| Physical Limitation Score | 37.1 ± 30.1 | 43.7 ± 32.0 |
| Symptom Frequency Score | 33.1 ± 28.6 | 50.5 ± 32.3 |
| Quality of Life Score | 27.1 ± 28.0 | 35.9 ± 29.8 |
| Social Limitation Score | 29.0 ± 26.1 | 40.9 ± 31.3 |
Change in NT-proBNP and BNP change from baseline during the study period is summarized for the Furoscix group
| pg/ml | Furoscix Infusor Prospective Treatment - Baseline | Furoscix Infusor Prospective Treatment - Day 30 |
|---|---|---|
| NT-proBNP | 823.4 ± 1043.9 | 700.7 ± 896.2 |
| BNP | 785.1 ± 1129.9 | 263.5 ± 384.0 |
The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| Please rate how comfortable or uncomfortable you felt wearing the device — Very Comfortable | 6 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Moderately Comfortable | 9 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Slightly Comfortable | 3 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Neither Comfortable or Uncomfortable | 0 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Slightly Uncomfortable | 5 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Moderately Uncomfortable | 1 |
| Please rate how comfortable or uncomfortable you felt wearing the device — Very Uncomfortable | 0 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Very Comfortable | 11 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Moderately Comfortable | 4 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Slightly Comfortable | 2 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Neither Comfortable or Uncomfortable | 4 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Slightly Uncomfortable | 1 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Moderately Uncomfortable | 1 |
| Please rate how comfortable or uncomfortable you felt upon removal of the device — Very Uncomfortable | 1 |
The Furoscix group was administered a Comfort of Wear Questionnaire on Day 2-4. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| If wearing the device interfered with activities of daily living - Walking — 1 - Not at all | 19 |
| If wearing the device interfered with activities of daily living - Walking — 2 - Probably Not | 1 |
| If wearing the device interfered with activities of daily living - Walking — 3 - Possibly | 1 |
| If wearing the device interfered with activities of daily living - Walking — 4 - Probably | 1 |
| If wearing the device interfered with activities of daily living - Walking — 5 - Completely | 1 |
| If wearing the device interfered with activities of daily living - Walking — Not Applicable | 1 |
| If wearing the device interfered with activities of daily living - Standing — 1 - Not at all | 19 |
| If wearing the device interfered with activities of daily living - Standing — 2 - Probably Not | 1 |
| If wearing the device interfered with activities of daily living - Standing — 3 - Possibly | 1 |
| If wearing the device interfered with activities of daily living - Standing — 4 - Probably | 1 |
| If wearing the device interfered with activities of daily living - Standing — 5 - Completely | 1 |
| If wearing the device interfered with activities of daily living - Standing — Not Applicable | 1 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — 1 - Not at all | 17 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — 2 - Probably Not | 5 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — 3 - Possibly | 0 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — 4 - Probably | 0 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — 5 - Completely | 1 |
| If wearing the device interfered with activities of daily living - Sitting reading watching TV — Not Applicable | 1 |
| If wearing the device interfered with activities of daily living - Lying down/napping — 1 - Not at all | 13 |
| If wearing the device interfered with activities of daily living - Lying down/napping — 2 - Probably Not | 4 |
| If wearing the device interfered with activities of daily living - Lying down/napping — 3 - Possibly | 2 |
| If wearing the device interfered with activities of daily living - Lying down/napping — 4 - Probably | 2 |
| If wearing the device interfered with activities of daily living - Lying down/napping — 5 - Completely | 0 |
| If wearing the device interfered with activities of daily living - Lying down/napping — Not Applicable | 3 |
| If wearing the device interfered with activities of daily living - Using the bathroom — 1 - Not at all | 17 |
| If wearing the device interfered with activities of daily living - Using the bathroom — 2 - Probably Not | 2 |
| If wearing the device interfered with activities of daily living - Using the bathroom — 3 - Possibly | 1 |
| If wearing the device interfered with activities of daily living - Using the bathroom — 4 - Probably | 3 |
| If wearing the device interfered with activities of daily living - Using the bathroom — 5 - Completely | 1 |
| If wearing the device interfered with activities of daily living - Using the bathroom — Not Applicable | 0 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — 1 - Not at all | 14 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — 2 - Probably Not | 4 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — 3 - Possibly | 1 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — 4 - Probably | 0 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — 5 - Completely | 0 |
| If wearing the device interfered with activities of daily living - Driving or riding in a car — Not Applicable | 5 |
The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.
| Participants | Furoscix Infusor Prospective Treatment |
|---|---|
| I think that I would like to use this product frequently — 1 - Strongly Disagree | 0 |
| I think that I would like to use this product frequently — 2 - Disagree | 2 |
| I think that I would like to use this product frequently — 3 - Neutral | 7 |
| I think that I would like to use this product frequently — 4 - Agree | 2 |
| I think that I would like to use this product frequently — 5 - Strongly Agree | 13 |
| I found the product unnecessarily complex — 1 - Strongly Disagree | 14 |
| I found the product unnecessarily complex — 2 - Disagree | 7 |
| I found the product unnecessarily complex — 3 - Neutral | 0 |
| I found the product unnecessarily complex — 4 - Agree | 1 |
| I found the product unnecessarily complex — 5 - Strongly Agree | 2 |
| I thought the product was easy to use — 1 - Strongly Disagree | 0 |
| I thought the product was easy to use — 2 - Disagree | 2 |
| I thought the product was easy to use — 3 - Neutral | 0 |
| I thought the product was easy to use — 4 - Agree | 4 |
| I thought the product was easy to use — 5 - Strongly Agree | 18 |
| I think that I would need the support of a technical person to be able to use this product — 1 - Strongly Disagree | 22 |
| I think that I would need the support of a technical person to be able to use this product — 2 - Disagree | 0 |
| I think that I would need the support of a technical person to be able to use this product — 3 - Neutral | 1 |
| I think that I would need the support of a technical person to be able to use this product — 4 - Agree | 0 |
| I think that I would need the support of a technical person to be able to use this product — 5 - Strongly Agree | 1 |
| I found the various functions in this product were well integrated — 1 - Strongly Disagree | 2 |
| I found the various functions in this product were well integrated — 2 - Disagree | 2 |
| I found the various functions in this product were well integrated — 3 - Neutral | 2 |
| I found the various functions in this product were well integrated — 4 - Agree | 4 |
| I found the various functions in this product were well integrated — 5 - Strongly Agree | 14 |
| I thought there was too much inconsistency in this product — 1 - Strongly Disagree | 18 |
| I thought there was too much inconsistency in this product — 2 - Disagree | 5 |
| I thought there was too much inconsistency in this product — 3 - Neutral | 1 |
| I thought there was too much inconsistency in this product — 4 - Agree | 0 |
| I thought there was too much inconsistency in this product — 5 - Strongly Agree | 0 |
| I would imagine that most people would learn to use this product very quickly — 1 - Strongly Disagree | 0 |
| I would imagine that most people would learn to use this product very quickly — 2 - Disagree | 0 |
| I would imagine that most people would learn to use this product very quickly — 3 - Neutral | 0 |
| I would imagine that most people would learn to use this product very quickly — 4 - Agree | 1 |
| I would imagine that most people would learn to use this product very quickly — 5 - Strongly Agree | 23 |
| I found the product very cumbersome to use — 1 - Strongly Disagree | 11 |
| I found the product very cumbersome to use — 2 - Disagree | 4 |
| I found the product very cumbersome to use — 3 - Neutral | 5 |
| I found the product very cumbersome to use — 4 - Agree | 1 |
| I found the product very cumbersome to use — 5 - Strongly Agree | 3 |
| I felt very confident using the product — 1 - Strongly Disagree | 0 |
| I felt very confident using the product — 2 - Disagree | 0 |
| I felt very confident using the product — 3 - Neutral | 0 |
| I felt very confident using the product — 4 - Agree | 5 |
| I felt very confident using the product — 5 - Strongly Agree | 19 |
| I needed to learn a lot of things before I could get going with this product — 1 - Strongly Disagree | 15 |
| I needed to learn a lot of things before I could get going with this product — 2 - Disagree | 3 |
| I needed to learn a lot of things before I could get going with this product — 3 - Neutral | 2 |
| I needed to learn a lot of things before I could get going with this product — 4 - Agree | 3 |
| I needed to learn a lot of things before I could get going with this product — 5 - Strongly Agree | 1 |
Collected over 30 Days from Enrollment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Furoscix Infusor Prospective Treatment | 0/24 (0%) | 6/24 (25%) | 18/24 (75%) |
| Event | Furoscix Infusor Prospective Treatment |
|---|---|
| Cardiac Failure CongestiveCardiac disorders | 1/24 |
| Food PoisoningGastrointestinal disorders | 1/24 |
| Tibia FractureInjury, poisoning and procedural complications | 1/24 |
| Diabetic KetoacidosisMetabolism and nutrition disorders | 1/24 |
| Hyperosmolar StateMetabolism and nutrition disorders | 1/24 |
| HypovolaemiaMetabolism and nutrition disorders | 1/24 |
| Acute Kidney InjuryRenal and urinary disorders | 1/24 |
| PolyuriaRenal and urinary disorders | 1/24 |
| LymphedemaVascular disorders | 1/24 |
| Event | Furoscix Infusor Prospective Treatment |
|---|---|
| Infusion Site BruisingGeneral disorders | 7/24 |
| Infusion Site PainGeneral disorders | 7/24 |
| DizzinessNervous system disorders | 3/24 |
| Infusion Site HemorrhageGeneral disorders | 2/24 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 2/24 |
| Urinary Tract InfectionInfections and infestations | 2/24 |
| Age, Continuous(years) | Furoscix Infusor Prospective Treatment |
|---|---|
| Mean | 56.3 ± 12.29 |
| Sex: Female, Male(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| Female | 9 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 10 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Subject's Insurance at baseline(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| Medicare | 8 |
| Medicaid | 4 |
| Commercial | 10 |
| Unknown | 2 |
| NYHA Classification(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| NYHA Class I | 0 |
| NYHA Class II | 4 |
| NYHA Class III | 20 |
| NYHA Class IV | 0 |
| Signs of volume expansion at baseline(Participants) | Furoscix Infusor Prospective Treatment |
|---|---|
| Jugular Venous Distention | 4 |
| Pitting Edema | 18 |
| Abdominal Distention | 9 |
| Pulmonary Congestion on Chest X-ray | 6 |
| Pulmonary Rales | 5 |
| History of Congestive Heart Failure (CHF)(Years) | Furoscix Infusor Prospective Treatment |
|---|---|
| Mean | 4.26 ± 4.917 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jun 2021, 7 months.
Results were first posted in Feb 2023, 1 year 8 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 7 months is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.